Suggested remit: To appraise the clinical and cost effectiveness of olezarsen within its marketing authorisation for treating familial chylomicronaemia syndrome.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6585
Provisional Schedule
- Committee meeting: 1:
- 25 June 2026
- Expected publication:
- 19 August 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email TAteam3@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Sobi
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action FCS
- Metabolic Support UK
- Professional groups
- HEART UK
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Arrowhead Pharmaceuticals (plozasiran) (confidentiality agreement signed, participating)
- Akcea Therapeutics (volanesorsen) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 November 2025 | Invitation to participate |
| 02 October 2025 | Note - Note added to the project documents |
| 23 July 2025 - 20 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6585 |
| 23 July 2025 | In progress. Scoping commenced. |
| 30 January 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual